TIDMFAB

Fusion Antibodies PLC

23 April 2018

23 April 2018

Fusion Antibodies plc

("Fusion" or the "Company")

Investor presentation

Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, announces that it will hold a presentation for investors on Wednesday, 2 May 2018.

The briefing by Paul Kerr, CEO of Fusion will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking. If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email fusion@walbrookpr.com.

Enquiries:

 
 Fusion Antibodies plc                                  www.fusionantibodies.com 
 Dr Paul Kerr, Chief Executive Officer                           Via Walbrook PR 
 James Fair, Chief Financial Officer 
 
 Walbrook PR                   Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com 
 Paul McManus                                           Mob: +44 (0)7980 541 893 
 Anna Dunphy                                            Mob: +44 (0)7876 741 001

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAPGUMUCUPRUBW

(END) Dow Jones Newswires

April 23, 2018 05:09 ET (09:09 GMT)

Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Fusion Antibodies Charts.
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Fusion Antibodies Charts.